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Abstract
Recent advances in understanding the multifaceted pathobiology of rheumatoid arthritis 
have highlighted the pivotal role and continuing crosstalk between activated immune 
cells, pro-inflammatory cytokines, and matrix-degrading mediators, promoting chronic 
inflammation as well as irreversible tissue damage within an autoimmune background. 
B cells are widely recognized as leading players in immune-mediated pathology based 
on their ability to produce not only different patterns of autoantibodies and driving cyto-
kine synthesis but also as independent antigen-presenting cells and by modulating the 
specific activation of T cells. Overwhelming evidence emphasized the role of BAFF, a 
B-cell-activating factor, and BAFF receptors (TACI, BCMA, BAFF-R) in promoting B-cell 
homeostasis, proliferation, and survival under normal and autoimmune systemic dis-
orders. We systematically reviewed data from literature focusing on BAFF, its homo-
log molecule APRIL, and BAFF-binding receptors biology, dysregulation of BAFF/BAFF 
receptor signaling in autoimmune settings, and current status of targeting BAFF/BAFF 
receptor pathway for rheumatoid arthritis.
Keywords: rheumatoid arthritis, autoimmunity, B-cell-activating factor (BAFF), BAFF-
bounding receptors, BAFF antagonists
1. Introduction
Rheumatoid arthritis (RA) is a chronic immuno-inflammatory disease characterized by 
a  multifaceted pathobiology, where a complex cytokine and cellular network contribute 
to excessive and extensive articular and systemic inflammatory events, accompanied by 
 progressive tissue damage [1–4].
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B cells are widely recognized as leading players in the mechanisms underlying the pathogen-
esis of RA based on their ability to produce not only different subsets of autoantibodies but also 
as independent antigen-presenting cells, cytokine synthesis, and modulators of T-cell activa-
tion. Moreover, their differentiation and survival are driven by positive feedback loops induced 
by cytokines, especially members belonging to the tumor necrosis factor (TNF) family [1–4].
Recent data highlighted the role of signaling crosstalk in B-lymphocytes, particularly of 
B-cell-activating factor (BAFF) and its receptors in early steps of the disease, advancing clini-
cal development of BAFF antagonists for the treatment of RA [2–5]. Acting as an innate cyto-
kine mediator, BAFF is known to modulate peripheral B- and T-cell homeostasis, promoting 
specific downstream signaling events through three different types of receptors [2, 4, 5].
Abnormal BAFF/BAFF receptor-signaling pathways were reported in several autoimmune 
disorders including systemic lupus erythematosus, Sjogren’s syndrome, ANCA-associated 
vasculitis, and RA [2, 4, 5]. Of interest, elevated BAFF levels were detected in synovial fluid, 
serum, and saliva in very early stages of RA, suggesting its involvement in cell-cell interac-
tions network in the synovial microenvironment, as well as B-cell activation and the develop-
ment of autoreactive B cells [2–4]. Furthermore, the overexpression of BAFF receptors, as well 
as disturbed autocrine and paracrine BAFF network, seems to be related to inflammatory 
events and RA progression [1–6].
Although clinical development of BAFF antagonists as potential therapeutic target for sys-
temic autoimmune conditions is promising, the benefit of specific agents such as belimumab, 
atacicept, or tabalumab in RA is controversial [2, 4, 6].
We systematically reviewed data from the literature focusing on the biology of BAFF, its 
homologue molecule APRIL and BAFF-binding receptors, dysregulation of BAFF/BAFF 
receptor signaling in RA and current status of targeting BAFF/BAFF receptor pathway.
2. BAFF and BAFF receptors physiology
2.1. BAF and APRIL
BAFF, also known as BLyS (B-lymphocyte stimulator), TALL-1 (TNF and apoptosis ligand-
related leukocyte-expressed ligand 1), zTNF4, TNFSF13B (TNF ligand superfamily member 
13B) or THANK, is a protein member of the TNF ligand family, critically involved in B-cell 
survival, maturation, and function [2–6]. As a vital cytokine for peripheral B-cell homeo-
stasis, BAFF is acknowledged as a key regulator for both innate and adaptive immune 
responses [2–5].
Under normal conditions, BAFF is mainly expressed and secreted by a variety of cells inclu-
ding monocytes, dendritic cells, neutrophils, stromal cells, and activated T cells [2–14] and is 
typically upregulated by different cytokines, such as TNF-α, IFN-γ, and TGF-β [2–14].
BAFF is recognized under two isoforms, a biologically active full-length isoform and the alter-
natively spliced one, 4BAFF, meaning a protein with a small peptide deletion which does 
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not bind to BAFF receptors, but has the ability to form heterotrimers with the original iso-
form [2–6]. Additionally, BAFF is expressed as a membrane-binding homotrimer and released 
as a soluble, biologically active molecule in peripheral blood after cleavage by a dedicated 
furinprotease [2, 4].
APRIL, a proliferation-inducing ligand known as the homolog molecule of BAFF or TNFSF13 
(TNF ligand superfamily member 13), is also a key cytokine for B-cell activation and matura-
tion; APRIL prompts B-cell proliferation, antibody class switching and survival, but is not 
required for the normal B-cell development [12–14].
Interestingly, BAFF and APRIL exhibit the ability to generate mixed molecules compris-
ing BAFF/APRIL hetero-trimers [2–14] and TWE-PRIL (TNFSF12), an APRIL extracellular 
domain/TWEAK intracellular domain hybrid molecule [2, 4], as well as ΔBAFF, an alterna-
tively spliced form of BAFF [4]. None of these molecules binds to BAFF receptors, but their 
co-expression with BAFF may have a deleterious impact on receptor signaling [2–14].
2.2. BAFF receptors signaling
Three distinct BAFF receptors typically expressed on B cells in different developmental stages 
are generally recognized: (i) BAFF receptor (BAFF-R, BR-3, TNFRSF13C or TNF receptor 
superfamily member 13C); (ii) transmembrane activator and calcium modulator ligand inter-
actor (TACI, TNFRSF13B or TNF receptor superfamily member 13B); and (iii) B-cell matura-
tion antigen (BCMA, TNFRSF17 or TNF receptor superfamily member 17) [2–14].
The expression of BAFF-binding receptors becomes evident only during the transitional 
stages of B-cells, varies according to the B-cell subset and is strictly dependent on various 
downstream mediators, further differentiation, maturation, and activation level as well [2–
14]. Moreover, each receptor triggers its own set of signaling pathways [2, 4].
Thus, BAFF-R is essentially engaged in naïve and memory B-cell populations, with the high-
est expression in follicular and marginal zone B-lymphocytes, and is upregulated by B-cell 
receptor on mature B cells and enables most of the BAFF-dependent actions [2–14]. BAFF-R 
appears to be the most important receptor for mature B-cell survival and homeostasis in 
peripheral B cells [5].
TACI remains the predominant receptor on marginal zone B cells and short-lived plasma 
cells, while BCMA is typically expressed by long-lived plasma cells being essential for their 
optimal generation [2, 4]. The ability of TACI to act as a sink for BAFF, preventing the 
attachment of BAFF to its BAFF-R, may also reflect mixed regulatory functions on B cells 
[2, 4, 5, 10–14].
Although BAFF-R/BR3 stands as a specific receptor for both soluble and membrane-bound 
BAFF, TACI and BCMA can also bind to the homologous proliferation-inducing ligand 
APRIL [2, 4, 10–14].
Each of the three receptors has a different pattern of expression and mediates distinct 
 functions [2, 4].
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2.3. BAFF and BAFF receptors functioning
It is widely accepted that BAFF plays a crucial role in B-cell homeostasis, adjusting their mat-
uration, proliferation, and survival under different backgrounds. BAFF may also indirectly 
interfere with T-cell functioning, providing several co-stimulatory signals in conjunction with 
T-cell receptor, mainly related to cellular proliferation and synthesis of mediators [2, 4].
Table 1 summarizes the BAFF/BAFF receptors functions in B and T cells (Table 1) [2–14].
2.3.1. BAFF and B-cell functioning
BAFF and APRIL mediate several important B-cell functions in normal settings, but 
 dysregulated BAFF/BAFF receptors represent a significant event in different autoimmune 
conditions [2–14].
First, BAFF enhances long-term B-cell survival primarily through NF-kB pathway by 
upregulating anti-apoptotic Genes, particularly the expression of Bcl-2 gene family mem-
bers [2–14]. While BAFF and APRIL typically improve the survival of plasmablasts, their 
role in promoting long-lived plasma cells persistence is still debatable [2, 4]. Moreover, 
either BAFF or APRIL accounts for the survival of plasma cells expressing TACI and/
or BCMA [2, 4, 10–14]. By contrast, memory B cells do not require BAFF nor APRIL for 
their proliferation and survival [2, 4]. Thus, their survival and reactivation are both BAFF-
independent [2, 4, 10–14]. Finally, BAFF-BAFF-R interface seems to be vital for the survival 
of B2 subpopulation from the transitional type 1 stage, with a minor input from TACI and 
without feedback from BCMA [2–14].
Second, BAFF enhances signaling through the B-cell receptor (BCR) by upregulating the 
expression of its co-receptors, namely CD21 and CD19, respectively [2–14]. The relation is 
bidirectional as BAFF-R expression is upregulated by B-cell receptor on mature B cells [2–14]. 
Additionally, there is a direct linkage between the intensity of BCR signaling and the extent 
of BAFF signal, particularly related to the non-classical NF-kB pathway which is operational 
for BAFF-R [2, 4–14]. Therefore, signaling through BAFF-R is able to promote B-lymphocytes 
survival in general, and individual late transitional and follicular B-cell survival [2–14].
Cell type Function
B cells Enhance B-cell and plasma cell survival
Co-stimulate B-cell proliferation
B-cell maturation
Promote B-cell differentiation from transitional type 1 to type 2 cells
Immunoglobulin synthesis
T-cell-independent and T-cell-dependent antibody response
T cells Enhance T-cell proliferation
Enhance cytokine synthesis
Dendritic cells Promote immune cell recruiting
Promote cytokine synthesis
Source: Adapted from Ref. [2].
Table 1. Overview of main BAFF biological functions in immune cells.
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Third, BAFF upregulates Toll-like receptor (TLR), endorses B-cell survival as well as Ig class 
switching and plasma cell differentiation [2–14]. The expression of BAFF-bound receptors on 
B cells, particularly TACI [2–14], is up-regulated via intracellular-activated TLR under the 
effect of specific immune complexes, with further relevance for augmented BCR-mediated 
signaling. Activated B cells by TLR-4 overexpress BAFF-R receptor types with subsequent 
susceptibility to apoptotic signals through Fas molecules [2–14].
Finally, the differentiation of peripheral autoreactive B cells depends on high BAFF levels [2–14].
2.3.2. BAFF and T-cell functioning: proliferation and cytokine production
While recent insights have extensively advanced our knowledge about BAFF/BAFF receptor 
intervention on B-cell activity in normal microenvironment and autoimmunity, the role of 
BAFF and APRIL in T-cell co-stimulation is still controversial [2, 4–14].
Classically, BAFF indirectly enhances T-cell proliferation [8] and arbitrates cytokine produc-
tion, particularly during inflammation. Hence, the expansion of T-cell population may occur 
as a consequence of primary B-cell expansion/proliferation rather than a result of direct inter-
vention of BAFF cytokine. Of interest, APRIL itself appears to mediate T-cell overflow [2–14]. 
T-cell-dependent immunoglobulin (Ig) responses strictly vary according to Ig subtype; IgM 
responses require BAFF intervention, whereas IgG responses are usually BAFF-independent 
[2–15]. Also, the intervention of BAFF receptors on T-cell function is debatable; while TACI 
might refashion T-cell functions, BAFF-R charge is unclear [2–14].
2.3.3. BAFF and dendritic cells functioning
It is increasingly recognized that BAFF influences dendritic cells to be actively involved in 
many physiologic as well as pathologic processes. Dendritic cells not only overexpress BAFF 
under different mediators (e.g., type I interferons) but also express BAFF receptors, predomi-
nantly TACI required for cellular proliferation and function [2–14]. The interaction between 
BAFF and dendritic cells stimulates immune cell trafficking and recruitment to inflammatory 
sites, and delivery of different cytokines and chemokines, mainly IL-1 and IL-6 [2–14].
3. BAFF and BAFF receptors in rheumatoid arthritis
Dysregulated BAFF/BAFF receptor signaling is clearly a trigger for autoimmunity in particu-
lar settings as is the case of systemic lupus erythematosus and RA [1, 2, 4, 5, 15–24]. To better 
understand the relevance of BAFF/BAFF receptor system in the complex pathobiology of RA 
with direct involvement in both early stages and disease progression, we emphasized seve-
ral aspects regarding cell networking and BAFF influences, BAFF levels, and BAFF receptor 
expression in RA [2, 4, 15–24].
3.1. BAFF and BAFF receptor influences on cell networking in rheumatoid arthritis
We already mentioned the effects of BAFF in B- and T-cell biological homeostasis in general, 
and we further provide information on how BAFF and APRIL influence immune cells and 
resident synovial cells in RA [2, 4, 15–24].
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RA is thought to be the result of an interplay between multiple cells and their products (cyto-
kines and mediators), from both innate and adaptive immunity that lead to systemic inflam-
matory and tissue-damaging events [1–4].
Persistent immune cell trafficking into the inflamed joints typically focuses on B- and 
T-lymphocytes, with special polarization for TCD4+ subpopulation, neutrophils, macro-
phages, and dendritic cells, which actively infiltrate the RA synovium and orchestrate inflam-
mation and cartilage damage [1–4]. At least three different histological subtypes of immune 
infiltrates are actually recognized within the RA synovitis, meaning diffuse, nodular infil-
trates, and lymphoid aggregates with germinal centers [2–4].
Excess of pro-inflammatory cytokines (mainly TNF-α, IL-1β, IL-6, IL-15, IL-17, and IL-23) 
and other inflammatory mediators (prostaglandin E2, reactive oxygen Species, nitric oxide) 
together with tissue-degrading enzymes (matrix metalloproteinases and other enzymes syn-
thetized by activated neutrophils) are essential performers, maintaining local cellular net-
working in RA joints [1–3].
As innate cytokines, BAFF and APRIL are potentially involved in the dysregulated immuno-
inflammatory synovial microenvironment, affecting both autocrine and paracrine feedback 
[1–6]. In addition, BAFF and APRILL are involved in an amplification loop which is locally 
activated by inflammation: B- and T-lymphocytes, together with plasmacytoid and myeloid 
dendritic cells, are interconnected through a continuing crosstalk [1–4]. Thus, B cells migrated 
to the inflamed tissues and activated produce pro-inflammatory and destructive cytokines 
and chemokines, but also exert their potent effector function by presenting self-antigens to 
and activating T cells [2–4]. Moreover, immune complexes as a result of aberrant functioning 
of B cells induce the activation of different subtypes of dendritic cells within the IFN direct 
supervision and further enhance B- and T-participation [4].
3.1.1. Neutrophils, macrophages, dendritic cells, and B-lymphocyte loop in rheumatoid arthritis
It is clear that activated neutrophils, macrophages, as well as dendritic cells represent fun-
damental sources of BAFF in the inflamed RA joints; however, these cells may have variable 
importance in different RA stages, with neutrophils releasing BAFF in early RA, while macro-
phages in established disease [1–4, 14–24].
Abundant BAFF levels further support a positive feedback from B-lymphocytes, the BAFF/
BAFF-R signaling being an important stimulator of B-cell proliferation, survival, and activa-
tion, with subsequent dysregulated B-cell functioning, with synthesis of various cytokines, 
and autoantibodies [1–4, 14–24].
Neutrophils incoming in the inflamed synovial joint is able to produce high levels of solu-
ble BAFF under the direct action of TNF-α and local G-CSF [1–4]. Additionally, through 
BAFF-R reverse signaling [2–4], macrophages are able to enhance MMP-9 and other matrix- 
degrading mediators [2–4]. Dendritic cells express BAFF molecule in early RA stages 
and turn into mature dendritic cells, mediating B-cell proliferation [2–4] with subsequent 
increase in antigen presentation, antibody production, immune complex formation, and 
cytokine secretion [1–4].
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3.1.2. Neutrophils, macrophages, dendritic cells, and T-lymphocytes loop in rheumatoid
BAFF may also interfere with T cells-dendritic cells interaction. BAFF is obviously involved 
in T helper 1 (Th1)-related immune responses [1–4, 14–24] and facilitates significant in situ 
CD4+ T-cell proliferation and Th1 as well as Th17 polarization [1–4]. Interestingly, pro-
inflammatory cytokines such as IL-1, IL-6, and TNF-α are involved in upregulation of BAFF 
expression on various activated cells in the synovial microenvironment (macrophages, den-
dritic cells, neutrophils) enhancing Th17 polarization and subsequent synthesis of IL-17 
cytokine [1–4].
3.1.3. Fibroblast-like macrophages, B- and T-cell loop in rheumatoid arthritis
Fibroblast-like macrophages are known to constitutively express BAFF in patients with RA, 
and BAFF expression is significantly upregulated under TNF-α and IFN-γ stimulation [2, 4]. 
Activated fibroblast-like macrophages are further able to secrete IL-6 and CXCL12, as well as 
adhesion molecules (VCAM-1) influencing the survival of mature B cells and synovial traf-
ficking [2, 4]. Recent data suggest that CD4+ T cells under BAFF activation are able to induce 
the proliferation of fibroblast-like macrophages, with consequent overexpression of various 
pro-inflammatory cytokines, particularly TNF-α, IL-1β, and IL-6 [2–4, 14–24].
Overall, various residents as well as recruited cells in rheumatoid synovium are responsible 
for BAFF synthesis, especially dendritic cells, macrophages and fibroblast-like macrophages, 
neutrophils, and CD4+ T cells. Further, BAFF interventions on the effector cell network (den-
dritic cells, macrophages and fibroblast-like macrophages, neutrophils, TCD4+ lymphocytes, 
and B cells) are able to promote by positive feedback their differentiation, proliferation, acti-
vation with subsequent cytokine production, and survival [2, 4].
3.2. Abnormal BAFF levels in rheumatoid arthritis
Elevated levels of BAFF are found in several inflammatory diseases (lupus, Sjogren’s, RA), 
and are related to disease activity [2–4]; RA exhibits a positive correlation between BAFF and 
disease activity, so that BAFF was recommended as a new index of RA activity [2, 4, 14–24].
Interestingly, a recent study designates BAFF as a predictor of RA prognosis and outcomes as 
serum level of BAFF parallels radiographic progression and higher plasma BAFF correlates 
with advanced radiographic joint damage [2, 4, 14–24].
Elevated levels of both BAFF and APRIL along with their receptors in patients with RA, 
particularly in rheumatoid factor (RF) positive, anti-cyclic citrullinated peptide antibodies 
(ACPA)-positive subtype, active, erosive disease, support their role in the pathobiology of 
the disease [2, 4, 14–24]. Although abnormal BAFF was typically found in both serum and 
synovial fluid in RA, significantly higher synovial levels suggest local BAFF production, 
driving the maturation as well as preserving autoreactive B cells within the inflamed tissue, 
with subsequent amplification of inflammatory processes and generation of autoantibodies 
[2, 4, 14–24]. Furthermore, seropositive RA status is clearly associated with higher concentra-
tions of BAFF than seronegative disease [2–4, 14–24], and there is a statistically significant 
correlation Between RF titer and BAFF level [2–4, 14–24].
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Finally, it seems that BAFF levels depend on RA stage, and disease duration as well 
[2, 4, 14–24]; thereby, patients with very early RA (disease duration less than 6 weeks) have 
highest BAFF levels, followed by those with established (lasting more than 12 months) and 
long-standing disease [2, 4, 14–24]. Undifferentiated early arthritis also has lower BAFF levels 
as compared to very early RA supporting a role for BAFF in the initial steps of disease develop-
ment [2, 4, 14–24].
However, local BAFF overexpression in RA joints is independent of the histologic subtype of 
RA synovitis (diffuse, nodular, and germinal center) [2, 4, 14–24]. BAFF also contributes to 
local B-lymphocyte function and survival, their activation and differentiation with subsequent 
production of autoantibodies [2, 4, 14–24]. Moreover, BAFF induces an autoreactive B-cell 
polarization as stressed by several studies in experimental arthritis models [2, 4, 14–24]. Thus, 
there is an interrelation between BAFF levels and humoral immune response [2, 4, 14–24], 
particularly RF, ACPA, as well as circulating immune complexes [2, 4, 14–24].
3.3. Abnormal expression of BAFF receptors in rheumatoid arthritis
BAFF receptors are also altered in RA [2, 4, 14–24]. The three receptor subtypes are expressed 
as follows: TACI-excessive levels are detected during first steps of RA development (early 
RA), BAFF-R has an obvious increase with disease progression, while BCMA expression 
has the same pattern as healthy population [2, 4, 14–24]. Furthermore, TACI receptor distri-
bution and expression are typically lower than BAFF-R/BR3, without any relation with the 
histological subtype of synovitis [2, 4, 14–24]. On the other hand, it seems that only BCMA 
and its gene expression correlate with different patterns of B- and T-cell distribution among 
the synovial tissue [2, 4, 14–24]. Thereby, BCMA is significantly enhanced in synovial tissue 
presenting with follicular lymphocyte aggregation with or without germinal centers forma-
tion than in diffuse lymphoid infiltration synovitis [2, 4, 14–24]. Finally, aberrant expres-
sion of BCMA in resident synovial cells, Fibroblast-like synoviocytes, was reported in RA 
[2, 4, 14–24].
4. Targeting BAFF and BAFF receptors for rheumatoid arthritis
Accumulating data on the importance of B cells in various autoimmune diseases have reshaped 
the therapeutic armamentarium, specifically directed toward B-lymphocytes [2, 4, 25, 26].
While playing a pivotal role in B-cell survival and functioning, BAFF/BAFF receptor system 
recently emerged as a reasonable target for different autoimmune conditions [2, 4, 25, 26]; 
furthermore, several BAFF antagonists are already under development exploring the appro-
priate therapeutic intervention based on BAFF blockade in RA [2, 4, 25, 26].
Generally, therapeutic BAFF antagonism accounts not only for direct B-cell depletion and 
indirect impairment of B-cell-mediated processes such as antigen presentation, cytokine syn-
thesis, and humoral immune response, but may also influence T-cell biology based on co-
stimulatory signals [2, 4, 25, 26].
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Several mechanisms were proposed to explain potential efficacy of BAFF/BAFF receptors 
antagonists in autoimmune conditions [2, 4, 25, 26]: (i) substantial B-cell depletion, par-
ticularly for bone-marrow-derived B2 subpopulation, known to undergo BAFF-mediated 
differentiation into follicular cells or marginal zone B cells [2, 4, 25, 26]; (ii) impaired immu-
noglobulin synthesis, especially in newly emerging B cells, while established memory B 
cells are spared; decreased transitional B-cell survival along with disturbed B-cell receptor 
co-signaling may further support altered immunoglobulin repertoire [2, 4, 25, 26]; (iii) indi-
rect effect on other cells belonging to the BAFF amplification loop (T cells, dendritic cells, 
and macrophages) and their inflammatory mediators promoting decreased antigen presen-
tation, decreased epitope spreading, immune complexes formation, and cytokine synthe-
sis [2, 4, 25, 26]; (iv) selective depletion of plasmablasts expressing different BAFF-binding 
receptors [2, 4, 25, 26].
At least two classes of BAFF antagonists are currently recognized including (i) BAFF-blockers 
or monoclonal anti-BAFF antibodies (e.g., belimumab and tabalumab) and (ii) receptor fusion 
proteins (e.g., atacicept), specifically binding soluble BAFF, membrane BAFF, or APRIL 
[2, 4, 25, 26].
A simplified view of BAFF/APRIL/BAFF-binding receptor pathway and their targeted ther-
apy in immune mediated is presented (Figure 1).
We reviewed the current status of targeting BAFF/BLyS, APRIL and their receptors in RA.
Figure 1. BAFF/APRIL/BAFF-binding receptor pathway and targeted therapy. Source: Adapted from Vincent F. et al., 
Nat Rev Rheum. 2014; Ref. [43].
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4.1. Belimumab
Belimumab, the first targeted biological therapy for systemic lupus erythematosus, is a 
recombinant fully human immunoglobulin G subclass 1 (IgG1k) anti-BAFF monoclonal anti-
body recently approved for antinuclear antibody-positive lupus, selectively targeting soluble 
BAFF, but not membrane-bound BAFF or other members of the TNF ligand family. Moreover, 
belimumab demonstrates inhibitory activity on all three BAFF receptors (TACI, BCMA, BR3) 
with equivalent potency [2, 4, 26–30].
BAFF overexpression in RA theoretically induces local (synovial) autoreactive B-cell prolifer-
ation and survival. Preventing BAFF from binding to B cells is able to impair B-cell-mediated 
autoimmune response and could be an attractive target for RA patients [2, 4, 26–30].
The efficacy and tolerability of a novel, fully human variant of anti-BLyS monoclonal anti-
body was further evaluated in patients with active RA non-responsive to standard therapy 
in different clinical trials [2, 4, 26–30]. While safety data are convincing across all the studies 
and belimumab seems to be a promising agent for a specific RA population, optimal clinical 
efficacy needs further evaluation [2, 4, 26–30]. The majority of trials have demonstrated posi-
tive outcomes under belimumab BAFF-blockade, meaning significant response rates accord-
ing to American College of Rheumatology (ACR) improvement ≥20% criteria but not ACR50 
or ACR70, specifically for RA patients classified as having high disease activity (disease 
activity score DAS28>5.1), RF and ACPA-positive status, naïve to other biologics including 
TNF antagonists, previous methotrexate failure or low baseline BAFF levels [2, 4, 26–30].
4.2. Tabalumab
Tabalumab, formerly LY2127399, is another fully human IgG4 anti-BAFF monoclonal anti-
body that binds to and neutralizes soluble and membrane-bound BAFF, but not to APRIL 
[2, 4, 25, 31–35].
Efficacy and safety of tabalumab in active RA despite ongoing methotrexate was assessed 
in several phase 2 and 3 randomized-controlled studies and their open-label extensions per-
formed on diverse patient populations comprising either bio-naive or bio-experienced RA 
with an inadequate response to TNF inhibitors (non-responders or intolerant) [2, 4, 25, 31–35]. 
Clinical efficacy parameters included standardized measures such as ACR20, ACR50, and 
ACR70 improvement criteria, DAS28-C-reactive protein (DAS28-CRP), and Health Assessment 
Questionnaire-Disability Index (HAQ-DI), while total B-cell counts or CD3-CD20 B cells and 
serum immunoglobulins were used for biological impact [2, 4, 25, 31–35]. Of interest, each 
one of the four phase 2 clinical trials (identifier NCT00308282, NCT00689728, NCT00785928, 
and NCT00837811) provided encouraging results under flexible doses of anti-BAFF and a 
background of stable methotrexate, with meaningful clinical and biological RA improvement 
as compared to placebo, regardless of prior treatment [2, 4, 25, 31–35]. However, tabalumab 
received no further validation following two phase 3 randomized, double-blind, placebo-con-
trolled studies aiming to demonstrate drug efficacy and safety in patients with moderate-to-
severe RA with inadequate response to one or more TNF inhibitors [25, 30, 34–36]. The interim 
analyses prompted the withdrawal of tabalumab due to lack of efficacy, not to safety concerns 
[2, 4, 25, 31–35].
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To summarize, although tabalumab showed clinical and biological efficacy in phase 2 clinical 
trials irrespective of prior exposure to synthetic remissive drugs (methotrexate) or biologics, 
phase 3 trials fail to promote clinical benefit in patients with moderate-to-severe RA with 
prior inadequate response to TNF antagonists. Despite demonstrating biological improve-
ment as supported by substantial change in B-cell count and decline in serum immunoglobu-
lin levels, it is obvious that targeting the BAFF pathway alone is not a feasible strategy in RA 
[2, 4, 25, 31–35].
4.3. Atacicept
Atacicept is a recombinant fusion protein between the extracellular domain of one of the BAFF 
receptors (TACI) and the Fc portion of human IgG1, able to inhibit B-cell maturation, differen-
tiation, and survival, as well as immunoglobulin synthesis by disconnecting B cells from stan-
dardized growth and development signals [2, 4, 25, 36–41]. In contrast to BAFF monoclonal 
antibodies, atacicept not only binds to and neutralizes BAFF but also targets APRIL molecule 
[2, 4, 25, 36–41] and could be an efficient target for RA treatment by inhibiting activation of 
TACI-mediated signaling [2, 4, 25, 36–42].
Preclinical and phase 1 clinical studies showed promising results as atacicept was well toler-
ated, with no increased incidence of infections, and displayed a meaningful biological activity 
with impaired levels of immunoglobulin, RF and ACPA, and a biphasic response in B-cell 
count [2, 4, 25, 36–41]. Moreover, atacicept induced substantial clinical improvement, despite 
the nonlinear pharmacokinetic profile [2, 4, 25, 36–41].
Nevertheless, AUGUST I (Clinical Trials.gov: NCT00430495) and AUGUST II (Clinical Trials.
gov: NCT00595413), two phase 2 clinical trials, failed to demonstrate the efficacy of atacicept 
in moderate-to-severe RA patients. Both studies were specifically designed to assess efficacy, 
safety, and biological activity of atacicept in RA with an inadequate response to TNF inhibi-
tors (AUGUST I) [2, 4, 25, 36–41] or biologically naive patients suboptimally controlled or 
intolerant to classic remissive agents (methotrexate) [2, 4, 25, 36–41].
Although the primary efficacy end point (ACR20 response) was not achieved in none of 
phase 2 studies, atacicept significantly reduced the immunoglobulin (IgM, IgG, and IgA) and 
rheumatoid factor levels in a dose-dependent manner. The safety profile was acceptable as 
atacicept did not show an increased susceptibility to infections, although the overall rate of 
adverse events was somewhat higher than placebo and lupus [2, 4, 25, 36–41].
To summarize, despite clinical and biological efficacy expressed in preclinical arthritis models 
and phase 1 clinical trial, phase 2 studies with atacicept fail to promote clinical benefit in 
patients with moderate-to-severe RA with inadequate response to either prior TNF antago-
nists or methotrexate [2, 4, 25, 36–41].
4.4. Other BAFF antagonists (AMG-623 and BR3-Fc)
Other BAFF-blockade agents are under development, targeting different BAFF receptor-
binding molecules. A good example is A-623, previously known as AMG-623, a polypeptide 
fusion protein containing both IgG and the ligand-binding section of the BAFF-R, able to 
block both membrane and soluble BAFF and, therefore, to impair normal B-cell functioning 
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[43]. Briobacept or BR3-Fc is another distinct BAFF-blocking molecule acting as a homodi-
meric fusion glycoprotein including the extracellular ligand-binding portion of BAFF-R and 
the Fc portion of an IgG. This new drug was typically designed to induce further B-cell apop-
tosis interfering with BAFF/BAFF-R signaling [2, 4, 43].
5. Conclusions
Abnormal BAFF signaling (throughout either overexpression of B-cell-related activation and 
survival genes, or BAFF receptors) represents an important step in the pathobiology of rheu-
matoid arthritis, particularly by promoting the development of autoreactive B cells in early 
disease, but also by supporting disease progression.
Although BAFF/APRIL/BAFF receptors targeting therapy seems to be an attractive option for 
systemic autoimmune conditions, particularly systemic lupus erythematosus, considerable 
response heterogeneity and safety concerns are reported in rheumatoid arthritis.
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